| INTRODUCTION
Primary sclerosing cholangitis (PSC) is a liver disease affecting the intra-and extrahepatic bile ducts. As the disease progresses, chronic inflammation leads to biliary fibrosis and ultimately end-stage liver disease. At present, there is no effective medical treatment for PSC, while liver transplantation is the only option to improve patient survival in selected patients although the disease may recur.
1,2 However, there is huge variation in the course of the disease with transplant-free survival ranging 12-21 years in different cohorts 3, 4 and with even larger inter-individual variation. There is an unmet need for early, accurate, non-invasive biomarkers to stratify risk of progression and adverse outcomes in PSC at the individual level.
Currently, there are no established biomarkers for predicting disease progression or clinical outcomes of PSC. 5 However, recent findings indicate that serological markers of fibrosis are promising prognosticators. The Enhanced Liver Fibrosis (ELF) test is a non-invasive, serum-based fibrosis marker panel based on three fibrosis markers which are all expressed during early stages of collagen deposition in early stages of fibrosis, namely the N-terminal procollagen type III (PIIINP), hyaluronic acid (HYA), and tissue-inhibitor of matrix metalloproteinase-1 (TIMP1). The ELF test was demonstrated to be a potent prognostic marker in PSC for the prediction of transplant-free survival 6 and the findings were validated in an international multicentre setting. 7 In PSC, fibrosis develops with the typical portal to portal biliary fibrosis pattern and is in addition characterised by concentric periductal fibrosis with so-called onion-skin appearance. 8 One possible method to differentiate early fibrosis from longer established PSC fibrosis is to study the extracellular matrix (ECM) remodeling in PSC.
The extracellular matrix can be subdivided in two compartments; the basement membrane, which is the outer extracellular matrix on which epithelial and endothelial cells attach, and the interstitial matrix, which is the inner extracellular matrix. 9 The basement membrane consists primarily of type IV collagen and laminin, whereas the interstitial matrix consists of fibrillar collagens type I, III and V as well as smaller amount of other nonfibrillar collagens. Matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) also play a pivotal role in extracellular matrix remodeling, favoring the tissue balance towards either more fibrogenesis or more fibrolysis. 10 The end product of tissue remodeling, that is, a neo-epitope resulting from a specific protein cleaved by a specific protease, is released into circulation and may serve as biomarker for that pathological process. A range of serological biomarkers specifically targeting the extracellular matrix remodeling have been developed in recent years, many of which have been shown to be related to various types of liver diseases, as either diagnostic, 11-13 prognostic 14, 15 or surrogate efficacy markers. [16] [17] [18] By combining both the protease and the protein, these biomarkers reflecting the balance between fibrogenesis and fibrinolysis may better assess the dynamic activity of a disease state as opposed to a static representation of stage, compared to other biomarkers targeting the intact protein.
In this study, we investigated four different extracellular matrix remodeling biomarkers reflecting both formation and degradation of the interstitial and basement membrane matrix, as prognostic markers for predicting transplant-free survival in PSC patients.
| PATIENTS AND METHODS

| Patient population
The study population included 138 PSC patients, previously described. 6 Biochemical analyses were performed using standard routine laboratory protocols for tests including platelets, creatinine, international normalised ratio (INR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and gamma-glutamyltransferase (GGT). The APRI (AST to platelet index) score was calculated using the published algorithm. 22 
| Biomarkers of extracellular matrix remodeling
We used validated competitive ELISAs (Nordic Bioscience, Herlev, Denmark) to assess true formation of interstitial matrix collagen type III and V (PRO-C3 and PRO-C5) and degradation of interstitial matrix collagen type III and basement membrane type IV collagen (C3M and C4M) in serum samples from PSC to ulcerative colitis patients.
All biomarkers were assessed in a blinded manner according to the manufacturer [23] [24] [25] [26] and samples were measured within the detection range.
| ELF test and ELF score
We analysed frozen serum samples from the PSC patients using the Chicago, IL, USA). Graphs were designed using GraphPad Prism version 7 (GraphPad Software, La Jolla, CA, USA).
3 | RESULTS
| Patients
Patient characteristics are shown in Table 1 . The majority of patients were male with a median age at diagnosis of 34 years. Overall 74%
of PSC patients had IBD with ulcerative colitis affecting 59%.
Patients were followed up for a median time period of 25.9 months, during which 33 patients underwent liver transplantation and 16 patients died. The indications for liver transplantation were decompensated liver disease (n = 9; 27%), intractable symptoms (n = 14; 42%) and biliary dysplasia (n = 10; 30%). The median (range) Mayo risk score at serum withdrawal was 0.12 (À2.37-4.13). The control cohort consisted of 52 patients with ulcerative colitis without PSC, 23 of whom had active disease, whereas 29 were in remission.
3.2 | ELF score compared to biomarkers of extracellular matrix remodeling in PSC and ulcerative colitis patients
All markers of extracellular matrix remodeling were significantly elevated in PSC patients compared to ulcerative colitis patients (P < 0.001) ( Figure 1 ). No differences between ulcerative colitis patients with active disease compared to patients in remission were observed for PRO-C3, PRO-C5, C3M or C4M (data not shown).
Moreover, the type III collagen balance showed relatively more type III collagen formation (PRO-C3) compared to type III collagen degradation (C3M) in PSC patients as demonstrated by a higher percentage difference between PSC and ulcerative colitis patients for PRO-C3 compared to C3M (65% vs 14%).
Similar to the extracellular matrix remodeling markers, the ELF score ( Figure 1 ) and its individual markers, PIIINP, TIMP-1 and hyaluronic acid ( Figure S1 ), were also significantly elevated in PSC patients as compared to ulcerative colitis patients (P < 0.01-P < 0.0001). No differences were observed between ulcerative colitis patients with active disease compared to patients in remission for neither ELF score nor its individual markers (data not shown).
| Performance of the ELF test compared to
biomarkers of extracellular matrix remodeling to discriminate between PSC patients with or without an end-point
To investigate prognosis, a primary end-point was defined as liver transplantation or death. In this study, 47 of the PSC patients either underwent liver transplantation or died within the follow-up period, whereas 91 patients remained alive and transplant-free.
AUROC analyses revealed that all four extracellular matrix remodeling biomarkers as well as APRI score and the ELF test were able to discriminate patients who reached an endpoint from those who did not with similar AUROCs (Table 2) , with a nonsignificant trend towards higher AUROC for Pro-C3 and Pro-C5 combined (AUROC 0.822).
On the basis of the cut-off values determined by the Youden index from the AUROC analyses for each novel marker and ELF test, we separated the patients into a high risk group and a low risk group according to survival. All markers except C3M showed significantly shorter survival time in patients with high baseline marker levels compared to patients with low baseline marker levels (Table 3) .
We then investigated the prognostic power of each of the markers in terms of predicting transplant-free survival. Figure S2 ).
| Determination of independent prognostic markers in PSC by Cox regression analyses
Univariate Cox proportional hazards regression analyses showed that all of the fibrosis markers were significantly associated with transplant-free survival (P < 0.05) ( Table 4) . Clinical characteristics (age, age at diagnosis, PSC duration), standard laboratory tests (bilirubin, AST, albumin and thrombocytes), the APRI score for fibrosis, the clinical PSC-specific Mayo risk score and the ELF test were also associated with prognosis as previously described for this patient panel (Table 4) (Tables S1 and S2 ).
Using multivariable Cox regression analyses, we investigated whether any of the markers were independently associated with transplant-free survival. In a first model (Table S3) (Table 5) .
Furthermore, we calculated the odds ratio for transplant-free survival in PSC comparing the lower tertile with the higher tertile of each marker. The ELF test predicted transplant-free survival with an odds ratio of 11.3 ( Figure 3 ). The two formation markers, PRO-C3
and PRO-C5, showed a slightly higher odds ratio as compared to the ELF test (13.8 and 12.5, respectively), whereas the two degradation markers, C3M and C4M, showed a slightly lower odds ratio as compared to the ELF test (6.1 and 8.7, respectively). Combining the two A combined endpoint was defined as all-cause death or liver transplantation. Prev, prevalence ie patients with end-point; AUROC, Area under the receiver operator characteristics curve; AUC, area under curve, Sens, sensitivity, spec, specificity, PPV, positive predictive value; NPV, negative predictive value; +LR, positive likelihood ratio; ÀLR, negative likelihood ratio; APRI, aspartate aminotransferase to platelet ratio index. Cut-off is given in units for the ELF ng/mL. Finally, defining a secondary end-point as death or liver transplantation due to hepatic decompensation (endpoint reached by n = 25 [18%]), we found that the discriminatory ability of all four extracellular matrix remodeling biomarkers were reproduced confirming the strengths of Pro-C3 (Table S4 ). Pro-C3 was associated with the highest risk of reaching the secondary endpoint (HR 3.59, 95% Cox proportional-hazards regression rates were calculated for tertiles of each of the novel extracellular matrix markers and ELF Test. PRO-C3 (collagen III formation marker) performed best out of the novel markers. Bilirubin, ALP, AST, ALT and platelet count were transformed by the natural logarithm prior to regression analyses due to a right-skewed distribution. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; APRI, AST to platelet index; IBD, inflammatory bowel disease; INR, international normalised ratio; HR, hazard ratio; CI, confidence interval.
T A B L E 2 AUROC analyses of ELF test and extracellular matrix remodeling markers for detecting patients with end-points
T A B L E 5 Multivariate Cox regression analyses to identify independent predictors of transplant-free survival in PSC patients. Cox proportional-hazards regression calculated for tertiles of each marker using forward elimination Our results showed that markers of extracellular matrix degradation represented by C3M and C4M were also elevated in PSC patients compared to ulcerative colitis controls, reflecting increased extracellular matrix turnover. These degradation markers were also associated with transplant-free survival, in particular, C4M was associated with clinical outcome independently of both the Mayo risk score and ELF test. Thickening of the biliary basement membrane is a hallmark of PSC, however, the specific pathogenesis is uncertain. 28 It is anticipated that epithelial cell damage and death result in disruption and destruction of the basement membrane. 35 Following disruption of the basement membrane the underlying connective tissue, mainly composed on fibrillar collagens such as type I, III, and V collagen, becomes fibrotic driven by activated hepatic stellate cells and Kupffer cells synthesising excessive amount of collagens and matrix metalloproteinases. Adjacent bile ducts are then surrounded by fibroblasts depositing thick bundles of fibrillar collagens ultimately leading to a thickening of the basement membrane giving rise to the characteristic onion skin appearance. 28, 35 This hypothesis can to some extent be confirmed by the findings in our study. The initial injury is described by an increase in C4M levels and may partly explain the less prognostic potential of this marker, as it may reflect disease onset rather than disease progression. Conversely, the inter- Further validation in independent PSC populations is warranted, and the fibrosis fingerprint of PSC should be further explored to identify the set of extracellular matrix markers that best capture the progression of fibrosis, and hence prognosis, in PSC, alone or in combination with clinically based scores such as the Mayo risk score or ALP. 36 Moreover, based on their reflection of the dynamic process of extracellular matrix remodeling, exploration of the potential role of these biomarkers as surrogate endpoints in clinical trials is warranted.
